Global Limb-Girdle Muscular Dystrophy Market - 2024-2031

Overview

The global limb-girdle muscular dystrophy market reached US$ 1.3 billion in 2023 and is expected to reach US$ 2.4 billion by 2031, growing at a CAGR of 7.4% during the forecast period 2024-2031.

Limb-girdle muscular dystrophy (LGMD) is a group of diseases that cause proximal muscle weakness and wasting in the limbs. The condition is caused by the inheritance of a disease-causing mutated gene whose original role is to encode the essential components required for muscle growth and maintaining muscle strength. There are two major groups of LGMDs called LGMD1 and LGMD2, which are classified based on respective inheritance patterns and genetic causes. If one copy of the abnormal gene is sufficient to cause the disease, it is said to be autosomal dominant and if two copies are needed, then the inheritance pattern is autosomal recessive.

The disease can affect the person at any life stage like childhood, adolescence, adulthood, and geriatric. If the condition affects the childhood phase, the progression can be rapid and the level of disability is higher.

There is no cure for limb-girdle muscular dystrophy at present, the current treatment options include physical therapy, corticosteroids, which provide symptomatic relief, and mobility aids which can help with movement. Currently, disease-modifying therapies such as gen therapies are being explored as a novel treatment option for this condition.

Market Dynamics: Drivers

Rising development of advanced therapies for limb-girdle muscular dystrophy

Currently, there is no specific treatment available for limb-girdle muscular dystrophy. Existing therapies such as physical therapy, respiratory and heart care, behavioral therapy, and some medication for symptomatic relief. All these treatments aim at alleviating symptoms and providing temporary relief to the patient. It is high time to bring novel therapies into the market that can modify the disease and help in the reversal of the condition. Several companies have been investing in and developing these novel therapies, which are currently in investigational trials and are anticipated to be launched into the market. These novel therapies, once launched, can revolutionize the limb-girdle muscular dystrophy market.

For instance, Sarepta Therapeutics, Inc. has been conducting phase 3 clinical trials for its gene therapy called Bidridistrogene Xeboparvovec for the treatment of limb-girdle muscular dystrophy. The primary completion date for the study is by January 2025 and the whole study is anticipated to be finished by 2029.

Moreover, ML Bio Solutions, Inc. has developed a novel drug called BBP-418 (Ribitol) which is currently being investigated in phase 3 of clinical trials. The study aims to evaluate the safety and efficacy of long-term administration of BBP-418 in limb-girdle muscular dystrophy patients. The study is anticipated to be finished by mid-2027.

Restraints

The high cost of treatment can be a restraining factor for the market growth in the forecast period. The patient with limb-girdle muscular dystrophy may need long-term treatment, which can be expensive for some patient populations. This can be troublesome to patients living in low and middle-income countries.

Market Segment Analysis

The global limb-girdle muscular dystrophy market is segmented based on type, treatment type, end-users, and region.

Physical therapy in the treatment type segment accounted for approximately 34.2% of the global limb-girdle muscular dystrophy market share

There is no specific treatment for limb-girdle muscular dystrophy. The condition is characterized by progressive proximal muscle loss in the limbs especially in the legs. This can cause symptoms such as pain, weakness, inability to walk and climb, and inability to lift heavy objects, eventually leading to the necessity of walking aids. The currently available treatment for this condition is only supportive in terms of physical therapy, occupational therapy, medication like corticosteroids to manage inflammation and respiratory and cardiac care.

Physical therapy plays a crucial role in managing the symptoms of this condition. Regular physical exercise can help to maintain mobility and delay muscle loss. The primary goal of physical therapy is to improve movement in the joints and to prevent their tightening. These problems can arise when movement is limited, so patients need to continue to move as much as they can. Activities such as aerobic exercise, submaximal strength training, upper limb exercises, and coordination activities can help the patient to be active and retain their mobility.

Market Geographical Share

North America is expected to dominate the market with a share of 41.3% in the global limb-girdle muscular dystrophy market

The region has well-established healthcare facilities that can provide tailored treatment options to patients. North America's advanced healthcare system enables patients to undergo screening at an early stage so that a tailored treatment can be planned according to their needs. The countries in the region such as the U.S. and Canada have highly advanced rehabilitation centers with ease of access to patients suffering from this condition.

In addition, the U.S. has organizations that strive to provide healthcare access to patients, support advanced research activities, and support care centers. For instance, The Muscular Dystrophy Association (MDA) is one such organization located in the U.S. in more than 150 of the top healthcare institutions. MDA's Care Center Network offers tens of thousands of appointments each year for individuals living with muscular dystrophy, ALS, and other neuromuscular diseases to access expert multidisciplinary care, and clinical trials, and to connect with MDA and the neuromuscular community.

Moreover, several medical institutes, research centers, and pharmaceutical and biopharmaceutical companies are creating innovations in the treatment of limb-girdle muscular dystrophy. For instance, the California Institute of Regenerative Medicine had received a grant for developing novel stem cell therapy which is aimed to promote healthy muscle growth in limb-girdle muscular dystrophy 2b patients. All these factors contribute to the region's dominance in the forecast period.

Market Segmentation

By Type

Limb-Girdle Muscular Dystrophy Type 1

Limb-Girdle Muscular Dystrophy Type 2

By Treatment Type

Physical Therapy

Medication

Occupational Therapy

Respiratory and Cardiac Care

Mobility Aids

Others

By End-Users

Hospitals & Clinics

Homecare

Others

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major players in the limb-girdle muscular dystrophy market include Horizon Therapeutics plc, Teva Pharmaceuticals USA, Inc., Pfizer Inc., Viatris Inc., Atamyo Therapeutics, Sarepta Therapeutics, Inc., Asklepios BioPharmaceutical, Inc., ML Bio Solutions, Inc., Genethon and Edgewise Therapeutics among others.

Why Purchase the Report?

To visualize the global limb-girdle muscular dystrophy market segmentation based on type, treatment type, end-users, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of limb-girdle muscular dystrophy market-level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as Excel consisting of key products of all the major players.

The global limb-girdle muscular dystrophy market report would provide approximately 62 tables, 54 figures, and 187 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies